Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru®, vs an Oil-Based Formulation, Epidyolex®, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study

Background Emerging evidence indicates that cannabidiol (CBD) may ofer meaningful therapeutic benefts across neurological, pain, and psychiatric disorders. Cannabidiol is already approved for the treatment of pediatric epilepsy. Owing to its high lipophilicity, it is typically delivered in oil-based formulations to overcome the low oral bioavailability of pure CBD. However, pharmacokinetic (PK) and safety data remain limited across diferent CBD formulations. This study evaluated the PK profle, tolerability, and safety of an encapsulated powdered emulsion formulation (CBtru®) compared with a marketed oil-based formulation (Epidyolex®/Epidiolex®) under fasted and fed conditions in healthy adults.